Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04873934 · ClinicalTrials.gov registry record · Phase 3
Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome
A Phase 3 study of Acute Coronary Syndrome, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT04873934 is a Phase 3 study of Acute Coronary Syndrome that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 400 participants, below the 2,712-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT04873934, a Phase 3 study of Acute Coronary Syndrome, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to study the effectiveness of implementation of a systematic LDL-C management pathway including treatment with inclisiran in participants who have experienced a recent acute coronary syndrome (ACS) and have an increased LDL-cholesterol (≥70 mg/dL) despite being treated with a statin drug.
Conditions Studied
Interventions
- DRUG Inclisiran
Study Locations (20)
California
- Central Cardiology Medical Center - Bakersfield
- The Heart Group Cardiovascular Associates Inc - Fresno
- Mission Heritage Medical Group - Mission Viejo
- Northbay Clinical Research LLC - Santa Rosa
- Clinnova Research Solutions - Torrance
- Harbor-UCLA Medical Center - Torrance
- Interv Cardiology Med Grp - West Hills
Florida
- Nova Clinical Research LLC - Bradenton
- Teradan Clinical trials LLC - Brandon
- Clearwater Cardiovascular and Interventional Consultants - Clearwater
- Cardiology Research Associates - Daytona Beach
- Holy Cross Hospital Inc - Fort Lauderdale
- Baptist Health Research Institute - Jacksonville
Colorado
- Aurora Denver Cardiology Associates - Aurora
- Colorado Springs Cardiology - Colorado Springs
- Colorado Heart and Vascular - Lakewood
District of Columbia
- Washington Hospital Center - Washington D.C.
- George Washington Univ Medical Ctr - Washington D.C.
Arkansas
- Northeast Arkansas Baptist Clinic - Jonesboro
Connecticut
- Cardiology Ass of Fairfield County - Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2021-06-24 |
| Est. Completion | 2024-08-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04873934
The ClinicalTrials.gov registry entry for NCT04873934 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,712-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (85% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Inclisiran is the first listed.
NCT04873934 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT04873934 about?
NCT04873934 is a clinical study titled "Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome". The purpose of this study is to study the effectiveness of implementation of a systematic LDL-C management pathway including treatment with inclisiran in participants who have experienced a recent acute coronary syndrome (ACS) and have an increased LDL-cholesterol (≥70 mg/dL) despite being treated w...
What is the current status of trial NCT04873934?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2021-06-24. Estimated completion is 2024-08-07.
What conditions does trial NCT04873934 study?
This clinical trial studies the following conditions: Acute Coronary Syndrome.
What interventions are being tested in trial NCT04873934?
The interventions under investigation include: Inclisiran (DRUG).
Who is sponsoring clinical trial NCT04873934?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04873934 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Coronary Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
RECRUITING · Phase 3
-
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
COMPLETED · Phase 3
-
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
COMPLETED · Phase 3
-
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
COMPLETED · Phase 3
-
A Polypill for Acute Coronary Syndrome
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.